Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 5 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Neoplasms 3 Lung Neoplasms 3 Solid Tumors 1 Rectal Neoplasms 1 Pleural Effusion 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Insulin-Like Growth Factor I, Resistance To 1 Fallopian Tube Neoplasms 1 Advanced Solid Tumors 1 Adenocarcinoma 1

Interventions

Fluorouracil 267 Oxaliplatin 266 Capecitabine 225 Leucovorin 209 Irinotecan 151 Radiotherapy 132 Bevacizumab 112 Cetuximab 81 Folfox protocol 49 Surgical Procedures, Operative 44 Radiation 41 Drug Therapy 41 Neoadjuvant Therapy 40 Chemoradiotherapy 33 Chemotherapy, Adjuvant 32 Panitumumab 27 XELOX 25 Magnetic Resonance Spectroscopy 22 Radiotherapy, Intensity-Modulated 21 Floxuridine 17 Biopsy 16 Nivolumab 15 Gemcitabine 15 Early Intervention, Educational 15 pembrolizumab 14 Laparoscopy 14 IFL protocol 14 Celecoxib 14 trifluridine tipiracil drug combination 13 Gene Expression Profiling 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rectal Neoplasms × dalotuzumab × Clear all

NCT01609231 2020-05-04

MK-0646-025

Merck Sharp & Dohme LLC

Phase 2 Terminated

11 enrolled 8 charts

Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡